Cargando…

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer

Detalles Bibliográficos
Autores principales:	Goode, Gennifer, Gunda, Venugopal, Chaika, Nina V., Purohit, Vinee, Yu, Fang, Singh, Pankaj K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453603/ https://www.ncbi.nlm.nih.gov/pubmed/28570622 http://dx.doi.org/10.1371/journal.pone.0179098

Ejemplares similares

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Correction: Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
por: Shukla, Surendra K, et al.
Publicado: (2014)

Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells
por: Gebregiworgis, Teklab, et al.
Publicado: (2017)

Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia
por: Shukla, Surendra K, et al.
Publicado: (2014)

MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic cancer metabolism
por: Shukla, Surendra K., et al.
Publicado: (2015)

Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
por: Shukla, Surendra K., et al.
Publicado: (2015)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Correction: Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming
por: Lopatina, Tatiana, et al.
Publicado: (2023)

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Validation of Metabolic Alterations in Microscale Cell Culture Lysates Using Hydrophilic Interaction Liquid Chromatography (HILIC)-Tandem Mass Spectrometry-Based Metabolomics
por: Gunda, Venugopal, et al.
Publicado: (2016)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
por: Behrens, Michelle E., et al.
Publicado: (2010)

MUC1 Oncoprotein Mitigates ER Stress via CDA-mediated Reprogramming of Pyrimidine Metabolism
por: Olou, Appolinaire A, et al.
Publicado: (2020)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

Correction: GPR110 promotes progression and metastasis of triple-negative breast cancer
por: Nam, Hye-Jung, et al.
Publicado: (2022)

Correction: M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
por: Dong, Fang, et al.
Publicado: (2022)

Correction: The MUC1 Extracellular Domain Subunit Is Found in Nuclear Speckles and Associates with Spliceosomes
por: Kumar, Priyadarsini, et al.
Publicado: (2012)

Correction: Single nucleotide polymorphisms within MUC4 are associated with colorectal cancer survival
por: Lu, Shun, et al.
Publicado: (2019)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
por: Ertay, Ayse, et al.
Publicado: (2021)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Metabolic reprogramming in triple-negative breast cancer
por: Wang, Zhanyu, et al.
Publicado: (2020)

Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
por: Singh, Balraj, et al.
Publicado: (2022)

Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM
por: Mörén, Lina, et al.
Publicado: (2018)

Differential Expression of Metabolic Genes in Tumor and Stromal Components of Primary and Metastatic Loci in Pancreatic Adenocarcinoma
por: Chaika, Nina V., et al.
Publicado: (2012)

Correction: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
por: Chapman, Margaret P., et al.
Publicado: (2019)

Correction for: A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells
por: Rajabi, Hasan, et al.
Publicado: (2019)

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

Correction: Cholesterol reprograms glucose and lipid metabolism to promote proliferation in colon cancer cells
por: Mayengbam, Shyamananda Singh, et al.
Publicado: (2023)

Correction: Telomere Dynamics in Human Cells Reprogrammed to Pluripotency
por: Suhr, Steven T., et al.
Publicado: (2010)

Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
por: Winter, Jordan M., et al.
Publicado: (2012)

Correction: MUC13 promotes the development of esophageal cancer by upregulating the expression of o-glycan process-related molecules
por: Han, Yi, et al.
Publicado: (2023)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Correction: Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype
Publicado: (2014)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ebr59suq1ljjbu0v0l96h77850